Dana-Farber research supports FDA approval of sevabertinib for HER2-mutant lung cancer
November 20, 2025
November 20, 2025
BOSTON, Massachusetts, Nov. 20 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
Dana-Farber research supports FDA approval of sevabertinib for HER2-mutant lung cancer
*
The US Food and Drug Administration has approved sevabertinib, an oral targeted therapy for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (also called ERBB2) mutations and who have prev . . .
* * *
Dana-Farber research supports FDA approval of sevabertinib for HER2-mutant lung cancer
*
The US Food and Drug Administration has approved sevabertinib, an oral targeted therapy for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (also called ERBB2) mutations and who have prev . . .